Biomedical subjects

James A Phillips

Publications and source records attributed to James A Phillips.

2 recordsLinked to original sources

PubMed2007

Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical efficacy and herpes-related quality of life.

BACKGROUND: Suppressive therapy has not been studied during the first year after acquisition of genital herpes, the time of maximum frequency of reactivation, potential for transmission, and impact on quality of life. OBJECTIVE: The objective of this study was to evaluate the effectiveness of suppressive therapy with valacyclovir initiated within 3 months of infection. STUDY DESIGN: The authors conducted a double-blind, randomized, controlled trial of 1.0 g valacyclovir daily versus placebo for 6 months in 119 patients. RESULTS: Herpes simplex virus (HSV) type 2 and HSV-1 were documented in 75 and 22 patients, respectively. In intention-to-treat analysis, annualized rates of symptomatic recurrences for valacyclovir and placebo, respectively, were 1.7 +/- 2.7 (mean +/- standard deviation) and 3.4 +/- 4.0 outbreaks per year (P = 0.012). Time to first recurrence was 80 +/- 47 days for valacyclovir and 54 +/- 49 days for placebo (P = 0.001). The differences in favor of valacyclovir were greatest in patients with confirmed HSV-2 infection. The Recurrent Genital Herpes Quality of Life score in HSV-2 infected patients rose 11.9 +/- 11.1 points for valacyclovir and 5.9 +/- 9.1 points for placebo (P = 0.040). CONCLUSIONS: Early suppressive therapy with valacyclovir reduces symptomatic recurrent outbreaks, especially in patients with HSV-2 infection. Valacyclovir therapy was associated with improved herpes-related quality of life.

Acyclovir↗

PubMed2006

Large gas-solid structural differences in complexes of haloacetonitriles with boron trifluoride.

The structural properties of the singly halogenated derivatives of CH(3)CN-BF(3) (X-CH(2)CN-BF(3): X = F, Cl, Br, I) have been investigated via single-crystal X-ray crystallography, solid-state infrared spectroscopy, and correlated electronic-structure theory. Taken together, these data illustrate large differences between the gas-phase and solid-state structures of these systems. Calculated gas-phase structures (B3PW91/aug-cc-pVTZ) of FCH(2)CN-BF(3), ClCH(2)CN-BF(3), and BrCH(2)CN-BF(3) indicate that the B-N dative bonds in these systems are quite weak, with distances of 2.422, 2.374, and 2.341 A, respectively. However, these distances, as well as other calculated structural parameters and normal-mode vibrational frequencies, indicate that the dative interactions do become slightly stronger in proceeding from F- to Br-CH(2)CN-BF(3). In contrast, solid-state structures for FCH(2)CN-BF(3), ClCH(2)CN-BF(3), and ICH(2)CN-BF(3) from X-ray crystallography all have B-N distances that are quite short, about 1.65 A. Thus, the B-N distances of the F- and Cl-containing derivatives contract by over 0.7 A upon crystallization. Large shifts in the vibrational modes involving motions of the BF(3) subunit parallel these structural changes. An X-ray crystal structure could not be determined for BrCH(2)CN-BF(3)(s), but the solid-state IR spectrum is consistent with those obtained previously for related complexes and suggests that the solid-state structure resembles those of the others, and in turn, implicates a large gas-solid structural difference for this species as well.

Journal Article↗